Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited: FY2025 Financial Analysis

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (“the Group”) has released its full-year 2025 audited financial results. This analysis highlights key financial metrics, major business developments, and the outlook for investors.

Key Financial Metrics and YoY Comparison

Historical Performance and Major Developments

• Revenue: Revenue declined sharply by 33% YoY due to the exclusion of Tianjin Zhongxin Medicine Co., Ltd. (TJZX Medicine) from consolidation, following its reclassification as an associate. However, the company’s industrial revenue increased.
• Gross Profit & Margin: Despite the revenue drop, gross profit rose 3% and margin surged to 72% (from 47%). This was mainly due to a better product mix and the consolidation change excluding lower-margin TJZX Medicine.
• Net Profit & EPS: Both net profit and EPS fell 5% and 4% respectively, mainly due to lower contribution from associates and reduced one-off gains from asset disposals.
• Divestments & Asset Sales:
  • Disposed the remaining 12% stake in Sino-American Tianjin SmithKline & French Lab., Ltd., booking a gain of RMB1.54 billion.
  • TJZX Medicine was deconsolidated after bankruptcy proceedings began.
• Exceptional Earnings/Expenses: The Group booked major one-off gains from associate disposals and lower impairment losses versus last year. Finance costs dropped by 97%, mainly due to the consolidation scope change.
• Balance Sheet: Cash and cash equivalents fell 65% YoY mainly due to elevated dividend payments and large investments in deposit products. Trade and other receivables rose 21% and payables increased 82%, primarily due to timing of dividend payments and working capital adjustments.
• Dividends:
  • FY2025: Interim dividend of RMB2.45/share (paid Feb 2026) and proposed final dividend of RMB23.4 per 10 shares (subject to AGM approval).
  • FY2024: Total dividend was RMB1.28/share or RMB985.8 million.
  • Total dividends for FY2025 (interim + proposed final): RMB4,674 million, a >374% increase YoY.
• Related-Party Transactions: Notable transactions include large deposits (RMB1.4 billion) with the Group’s controlling shareholder’s finance company, and provision of guarantees for associates’ borrowings. All are within shareholder-approved limits.
• Cash Flows: Operating cash flow dropped 53% mainly due to income tax payments on associate disposals. Investing cash outflows increased, reflecting higher purchases of deposit products and lower asset sale proceeds. Financing cash outflows rose due to increased dividend payouts.

Chairman’s Statement & Business Outlook

“In 2025, the traditional Chinese medicine (TCM) proprietary products industry entered a critical transition period of high-quality development. Amid the interplay of multiple factors including policies, market dynamics and technological advancements, the industry faces unprecedented development opportunities while also needing to evolve amid ongoing transformation.

From an opportunity perspective, the policy environment continues to improve. Reforms in TCM drug review and approval mechanisms continue to deepen, creating a fast track for innovative TCM products with clinical value and stimulating corporate R&D vitality. On the demand side, market demand continues to show strong and resilient growth. Accelerated population ageing, the rising prevalence of chronic disease management and the widespread adoption of ‘preventive healthcare’ philosophy have broadened the application prospects of TCM proprietary products in areas such as health supplements, rehabilitation and wellness, with increasing demand for consumer-oriented products. Meanwhile, technological transformation is injecting new momentum into the traditional industry. The adoption of intelligent manufacturing technologies is gradually transforming TCM production methods, improving product quality consistency and production efficiency. Big data, artificial intelligence and other technologies are also beginning to penetrate new drug R&D and clinical validation processes, promoting evidence-based medicine research and supporting the modernisation of TCM. Furthermore, channel reforms integrating online and offline platforms, particularly the deepening of ‘Internet + Pharmaceutical’, are providing branded TCM products with broader market reach and more precise marketing opportunities.

As the industry continues to advance, it is also undergoing profound self-adjustment. At the policy level, the normalisation of volume-based procurement is guiding the industry towards greater cost-effectiveness, prompting companies to optimise internal management and improve operational efficiency. The comprehensive upgrade of the regulatory framework, particularly the increasingly stringent drug quality standards and traceability requirements, has set higher benchmarks for the industry, encouraging companies to strengthen quality control across the entire process from sourcing to production, and achieve a transition from traditional production methods to modernised and standardised management. The evolving market environment also brings new challenges: traditional retail channels are experiencing structural traffic adjustments, while the rapid growth of online channels tests companies’ brand adaptability and digital service capabilities.

As a full-industry-chain modern TCM enterprise, the Group leverages its time-honoured brand heritage, exclusive product portfolio and complete industrial chain to continuously strengthen its brand building, marketing transformation, R&D innovation, quality control and organisational management. Sales of core product have maintained steady growth, while new retail initiatives, academic promotion and international market expansion proceed in parallel. Scientific research is focused on in-depth studies of clinical value, while the supply chain and production processes continue to enhance quality and efficiency. Internal management and organisational structures are continuously optimised, leading to sustained improvements in brand influence, product competitiveness and operational efficiency, further consolidating the Group’s core competitive advantages. In 2026, the Company will adopt a brand-led strategy as its core, focusing on advancing R&D innovation, marketing transformation, operational excellence, organisational revitalisation and strategic coordination to drive high-quality development.”

Tone: The Chairman’s Statement is optimistic and forward-looking, emphasizing resilience, innovation, and modernization amid industry transformation and regulatory tightening. It acknowledges challenges but highlights strategic strengths and ongoing improvement.

Events and Risks Affecting the Business

• Legal Disputes: Tianjin Shin Poong Pharmaceutical Co., Ltd. was deconsolidated following court-ordered bankruptcy liquidation; no material losses or ongoing control risk remain for the Group.
• Macroeconomic & Regulatory Trends: The TCM industry is experiencing regulatory tightening, shifting consumption habits, and increased digitalization, all of which the Group aims to leverage.
• No Share Dilution or Buybacks: There were no share buybacks, placements, or dilution events in 2025. Share capital remained unchanged.
• Large Related-Party Transactions: Substantial funds placed with the controlling shareholder’s finance company, but all within board and shareholder-approved limits and fully disclosed.

Conclusion & Investment Recommendation

Overall Assessment: The Group delivered resilient profitability and significantly increased dividends despite a sharp drop in revenue, driven largely by changes in consolidation scope and major asset disposals. Gross profit and margin improved, reflecting a stronger product mix. The balance sheet remains robust, with increased investment in fixed deposits and manageable debt. The current industry and regulatory environment is challenging but offers strategic opportunities, which management appears well-positioned to exploit.

• For Current Shareholders: The high dividend payout and strong gross margins are positives, but investors should keep an eye on the Group’s ability to grow revenues organically without further one-off disposals. Consider holding if you seek yield, but monitor quarterly operating results closely for sustainable growth.
• For Potential Investors (Not Currently Holding): The stock may be attractive for dividend-focused investors, but revenue headwinds and dependency on asset sales for profit growth are risks. It may be prudent to wait for evidence of organic revenue and profit recovery post-restructuring before initiating a position.

Disclaimer: This analysis is based strictly on information disclosed in the company’s FY2025 report. It does not constitute investment advice. Please conduct your own research and seek professional advice before making investment decisions.

View TJ DaRenTang USD Historical chart here